Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Background: Patients with locally advanced esophageal cancer who are treated with trimodality therapy have a high recurrence rate. Preclinical evidence suggests that inhibition of cyclooxygenase 2 (COX2) increases the effectiveness of chemoradiation, and observational studies in humans suggest that...

Full description

Bibliographic Details
Main Authors: Cleary, James M., Mamon, Harvey J., Szymonifka, Jackie, Bueno, Raphael, Choi, Noah, Donahue, Dean M., Fidias, Panos M., Gaissert, Henning A., Jaklitsch, Michael T., Kulke, Matthew H., Lynch, Thomas P., Mentzer, Steven J., Meyerhardt, Jeffrey A., Swanson, Richard S., Wain, John, Fuchs, Charles S., Enzinger, Peter C.
Other Authors: Univ Arizona, Ctr Canc, St Josephs Hosp & Med Ctr
Language:en
Published: BioMed Central 2016
Subjects:
Esophageal cancer
Neoadjuvant therapy
Chemoradiation
Cyclooxygenase 2 inhibition
Online Access:http://hdl.handle.net/10150/618723
http://arizona.openrepository.com/arizona/handle/10150/618723

Internet

http://hdl.handle.net/10150/618723
http://arizona.openrepository.com/arizona/handle/10150/618723

Similar Items